sarscoronaviru
causal
agent
outbreak
entri
cell
depend
upon
bind
viral
spike
protein
cellular
receptor
cleavag
spike
protein
host
cell
proteas
cathepsin
l
cathepsin
b
ctslb
crucial
element
lysosom
pathway
enzym
almost
exclus
locat
lysosomesctsl
disrupt
offer
potenti
therapi
mechan
disrupt
includ
decreas
express
ctsl
direct
inhibit
ctsl
activ
affect
condit
ctsl
environ
increas
ph
lysosom
conduct
high
throughput
drug
screen
gene
express
analysi
identifi
compound
would
downregul
express
ctslctsb
one
top
signific
result
shown
downregul
express
ctsl
gene
amantadin
amantadin
approv
us
food
drug
administr
prophylact
agent
influenza
later
parkinson
diseas
avail
gener
drug
amantadin
addit
downregul
ctsl
appear
disrupt
lysosom
pathway
henc
interf
capac
viru
replic
act
lysosomotrop
agent
alter
ctsl
function
environ
hypothes
amantadin
could
decreas
viral
load
posit
patient
may
serv
potent
therapeut
decreas
replic
infect
viru
like
lead
better
clinic
outcom
clinic
studi
need
examin
therapeut
util
amantadin
infect
authorfund
right
reserv
reus
allow
without
permiss
recent
novel
type
highli
virul
betacoronaviru
discov
patient
pneumonia
unknown
caus
sever
acut
respiratori
syndrom
coronaviru
detect
sequenc
sampl
found
caus
sever
respiratori
diseas
human
outbreak
result
global
epidem
number
confirm
case
surpass
march
genom
share
similar
sarscov
even
similar
bat
coronaviru
batcov
coronavirus
character
larg
genet
divers
frequent
recombin
genom
henc
pose
challeng
term
public
health
current
base
viral
genom
predict
genet
substitut
per
year
understand
mechan
action
viru
fundament
step
delin
optim
therapeut
agent
similar
sarscov
enter
cell
mean
bind
cellular
receptor
includ
angiotensinconvert
enzym
membran
bound
protein
type
membran
protein
express
lung
heart
kidney
intestin
decreas
express
associ
cardiovascular
diseas
structur
basi
recognit
recent
map
cryoem
structur
full
length
viral
spike
protein
target
human
complex
report
author
show
viral
protein
bind
least
time
tightli
compar
spike
protein
previou
sarscov
strain
viral
spike
glycoprotein
protein
mediat
receptor
recognit
recent
structur
protein
describ
protein
cleav
two
subunit
cleavag
protein
host
proteas
critic
viral
infect
exist
cell
via
lysosom
host
proteas
depend
entri
critic
step
sarscov
take
advantag
endosom
cystein
proteas
cathepsin
b
l
ctsl
ctsb
cathepsin
l
peptidas
preferenti
cleav
peptid
bond
aromat
residu
hydrophob
residu
posit
ctsl
activ
ph
presenc
thiol
enzymat
stabil
depend
ionic
strength
cathepsin
l
proteolysi
shown
import
mechan
ebola
well
sarscov
outbreak
process
viral
glycoprotein
cell
membran
fusion
specif
protein
cleav
host
cell
proteas
expos
fusion
peptid
domain
lead
fusion
viral
cellular
membran
releas
viral
genom
cytoplasm
host
cell
cleavag
protein
occur
domain
subsequ
within
domain
proxim
fusion
peptid
cleavag
site
believ
necessari
viral
entri
host
cell
cleavag
site
threonin
methionin
posit
cleavag
site
ident
sarscov
shown
cleav
cathepsin
l
catl
ctsl
lysosom
cystein
proteas
encod
gene
also
furinlik
proteas
cleavag
site
found
sarscov
arginin
serin
posit
site
may
cleav
furin
viral
egress
protein
might
also
prime
inhibit
shown
suppress
sarscov
infect
furthermor
whose
express
correl
sarscov
infect
upper
lobe
lung
interf
spike
protein
process
host
cell
whether
affect
environ
modul
gene
express
level
henc
offer
potenti
therapeut
strategi
genet
variat
ctsl
gene
could
theori
affect
propag
capac
viru
furthermor
ctsl
polymorph
could
affect
suscept
exampl
individu
certain
genet
variant
reduc
express
cathepsin
l
turn
could
protect
lower
viral
titer
addit
element
host
mhc
ctl
mediat
immun
respons
might
affect
viral
prolifer
suscept
factor
span
ethnic
background
age
relat
group
comorbid
condit
novel
therapeut
identifi
high
throughput
screen
assay
shown
block
cleavag
spike
protein
cathepsin
l
cathepsin
b
proteas
predictedselect
bind
site
viabl
approach
function
target
limit
viru
therapeut
mechan
action
could
involv
lower
modul
express
ctsl
affect
condit
ctsl
lysosom
environ
modul
ph
test
agent
could
help
identifi
potenti
therapeut
agent
capac
decreas
express
ctsl
gene
discuss
identif
agent
particular
amantadin
one
compound
propos
clinic
studi
conduct
examin
whether
amantadin
could
use
treat
patient
infect
discov
potenti
pharmaceut
agent
abl
modul
molecular
signatur
implic
sarscov
pathophysiolog
screen
compound
belong
differ
therapeut
class
supplement
fig
xx
screen
conduct
use
human
retin
pigment
epithelia
cell
line
gene
express
chang
collect
across
gene
cell
line
initi
select
well
suit
model
studi
compound
affect
neuron
type
cell
particular
antipsychot
express
varieti
well
known
neuron
cell
surfac
receptor
includ
dopamin
receptor
serotonin
receptor
muscarin
receptor
histamin
receptor
describ
discoveri
ctslb
lysosomotrop
signatur
might
give
insight
therapeut
potenti
drug
analyz
express
profil
ctsl
across
drug
test
order
find
posit
hit
select
result
caus
decreas
ctsl
express
least
fold
top
drug
target
consist
drug
variou
therapeut
area
muscl
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
relax
antihistamin
antiepilept
anticholirgen
antivir
drug
would
decreas
ctsl
express
among
top
result
amantadin
known
safe
antivir
agent
previous
use
treat
patient
influenza
amantadin
hydrochlorid
among
top
drug
within
top
differ
lysosomotrop
alkalin
agent
physic
chemic
properti
amantadin
lead
lysosom
accumul
lysosomotrop
drug
affect
lysosom
ph
alter
block
ca
signal
lysosom
membran
permeabllil
enzym
activ
inhibit
storag
materi
accumul
amantadin
behav
lysosomotrop
substanc
pass
easili
lysosom
membran
accumul
could
lower
ph
lysosom
thu
inhibit
proteas
activ
amantadin
also
block
assembl
influenza
viru
viral
replic
moreov
amantadin
may
directli
affect
viral
entri
direct
manner
downmodul
ctsl
lysosom
pathway
gene
pk
profil
drug
make
particularli
amantadin
hcl
ir
avail
tablet
equival
mg
base
amantadin
ml
syrup
equival
ml
base
amantadin
typic
administ
twice
daili
sinc
ctsl
top
differenti
express
transcript
decid
extend
analysi
gene
downregul
amantadin
among
top
differenti
express
probe
gene
least
express
reduct
found
gene
relat
lysosom
moreov
number
top
signific
pathway
enrichr
enrich
analysi
kegg
lysosom
amantadin
signific
effect
lysosom
pathway
gene
shown
figur
tabl
investig
natur
variat
ctsl
express
across
ethnic
focus
common
rare
variant
genotypetissu
express
gtex
project
provid
genotyp
inform
gene
express
level
across
human
tissu
donor
allow
us
examin
express
pattern
ctsl
across
tissu
well
across
individu
figur
show
express
ctsl
across
differ
organ
associ
cell
type
ctsl
wide
express
mani
crucial
organ
high
lung
nerv
tibial
adipos
arteri
whole
blood
sever
other
look
eqtl
variant
ctsl
found
signific
lung
specif
variant
confer
highli
variabl
express
genotyp
supp
fig
confer
lower
baselin
express
like
associ
better
respons
convers
higher
express
perhap
higher
viral
load
observ
presenc
seri
splice
qtl
henc
variant
affect
splice
ratio
transcript
signific
present
lung
tissu
ctsl
gtex
analysi
point
potenti
protect
suscept
certain
individu
interestingli
altern
splice
ctsl
transcript
lung
display
tissu
specif
regulatori
program
recent
function
studi
point
common
variant
ctsl
proxim
promot
posit
confirm
alter
transcript
via
alter
xenobiot
respons
element
similar
variant
like
affect
natur
divers
baselin
express
henc
viral
fit
cell
entri
addit
check
gnomad
databas
number
rare
variant
variat
toler
statu
ctsl
result
show
averag
missens
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
variant
ctsl
gene
predict
lossoffunct
variant
toler
pli
togeth
signific
eqtl
indic
larg
effect
genet
variat
ctsl
express
variat
thereof
also
wide
express
multipl
tissu
includ
gi
system
lung
kidney
high
express
ctsl
transcript
seri
organ
could
explain
viral
manifest
tissu
recent
studi
show
viral
presenc
stool
sampl
infect
individu
well
effect
viru
seen
across
tissu
assum
enough
express
tissu
viral
protein
bind
target
cell
decreas
express
enzym
like
potenti
mechan
would
lower
capac
viru
exit
cell
anoth
viabl
option
lysosom
dysfunct
interfer
mani
way
viral
replic
viru
go
get
assembl
get
readi
subsequ
replic
given
one
abl
perturb
lysosom
function
microenviron
may
offer
protect
viru
decreas
sever
symptom
seen
amantadin
downregul
cathepsin
l
number
key
lysosom
enzym
hypothes
lysosom
dysfunct
induc
amantadin
administr
protect
viral
entri
replic
hypothesi
peopl
certain
lysosom
storag
diseas
resist
one
virus
along
line
suggest
evid
true
neimman
pick
type
c
storag
cholesterol
transport
disord
offer
resist
ebola
patient
cell
line
even
interest
attach
articl
bat
show
select
sensit
ebola
versu
marburg
virus
interf
lysosom
milieu
protect
effect
coronaviru
know
use
cathepsin
l
ph
sensit
enzym
process
cleavag
spike
protein
amantadin
would
predict
physic
chemic
properti
accumul
lysosom
rais
ph
like
enough
interfer
cathepsin
l
function
gene
express
pattern
report
paper
suggest
gener
lysosom
program
downregul
like
common
set
transcript
factor
amantadin
could
henc
use
potent
agent
decreas
viral
load
administ
earli
enough
cours
infect
accumul
lysosom
effect
could
reduc
viral
load
may
decreas
intrahost
organ
spread
decreas
associ
diseas
sever
progress
studi
includ
clinic
trial
would
requir
order
examin
role
amantadin
administr
treatment
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
drug
screen
one
use
previou
studi
retin
pigment
epithelia
cell
line
chosen
establish
databas
drug
profil
noncancer
human
origin
normal
karyotyp
also
easili
grown
monolay
plate
cell
line
propag
accord
supplier
specif
atcc
manassa
va
compound
obtain
sigma
st
loui
mo
vanda
pharmaceut
washington
dc
cell
aliquot
plate
cellswel
incub
h
prior
provid
fresh
media
drug
drug
vehicl
water
dimethyl
sulfoxid
ethanol
methanol
phosphatebuff
salin
solut
drug
dilut
fold
buffer
advanc
cultur
medium
invitrogen
carlsbad
ca
contain
nonessenti
amino
acid
mgl
sodium
pyruv
condit
signific
chang
ph
expect
confirm
monitor
ph
indic
present
medium
final
drug
concentr
chosen
believ
fit
rang
physiolog
relev
microscop
inspect
well
conduct
end
treatment
discard
sampl
cell
morpholog
chang
consist
apoptosi
also
verifi
drug
precipit
cultur
medium
cell
harvest
h
treatment
rna
extract
use
rneasi
protocol
qiagen
valencia
ca
gene
express
probe
set
gene
gener
microarray
follow
manufactur
instruct
affymetrix
santa
clara
ca
drug
profil
duplic
triplic
multipl
vehicl
control
plate
total
microarray
analyz
includ
antipsychot
compound
vehicl
control
raw
scan
data
first
convert
averag
differ
valu
use
ma
affymetrix
averag
differ
valu
treatment
control
data
set
minimum
threshold
treatment
instanc
probe
set
rank
base
amplitud
level
express
rel
vehicl
control
averag
control
one
use
amplitud
defin
ratio
express
tv
correspond
treatment
instanc
v
vehicl
instanc
drug
group
profil
creat
use
novel
weight
influenc
model
rank
rank
wimrr
method
underscor
rank
probe
set
across
entir
gene
express
profil
rather
specif
chang
express
level
wimrr
take
averag
rank
probe
set
across
member
group
rerank
probe
set
smallest
averag
rank
largest
averag
rank
geneset
enrich
metric
base
kolmogorovsmirnov
ks
statist
specif
given
set
probe
ks
score
give
measur
posit
neg
set
probe
occur
within
profil
anoth
treatment
instanc
copyright
holder
preprint
peerreview
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
f
g
u
r
e
e
x
p
r
e
n
f
c
h
e
p
n
l
c
l
c
r
u
e
b
e
w
e
e
n
f
e
l
e
r
e
n
l
e
b
l
u
e
